Holmium-166 Retrospective Collection of Real-World Data (RECORD)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Aalst, Belgien
- ASZ Aalst
-
Aalst, Belgien
- OLV Aalst
-
Bruxelles, Belgien
- CUB Hopital Erasme
-
-
-
-
-
Utrecht, Holland
- University Medical Center Utrecht
-
-
-
-
-
Rome, Italien
- IFO IRCCS - Istituto Nazionale Tumori Regina Elena
-
-
-
-
-
Porto, Portugal
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
-
-
-
-
Basel, Schweiz
- Universitätsspital Basel
-
-
-
-
-
Barcelona, Spanien
- Hospital Universitari Germans Trias i Pujol
-
-
-
-
-
Dresden, Tyskland
- Universitatsklinikum Carl Gustav Carus
-
Herford, Tyskland
- Klinikum Herford
-
Jena, Tyskland
- Universitatsklinikum Jena
-
Rostock, Tyskland
- Universitätsmedizin Rostock
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patient with diagnosis of primary liver tumor or metastases in the liver.
- Patients treated with QuiremScoutTM Holmium-166 Microspheres and/or QuiremSpheresTM Holmium-166 Microspheres from 15 July 2019 to 15 July 2021.
- Patient is ≥ 18 years.
- If required by national regulation, patient has understood and signed written informed consent to retrospective data collection.
Exclusion Criteria:
- Patients previously included in prospective interventional study with QuiremScoutTM Holmium-166 Microspheres and/or QuiremSpheresTM Holmium-166 Microspheres.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Frequency and Severity of Adverse Events
Tidsramme: 30 months
|
The primary safety endpoint is defined in terms of incidence of adverse events CTCAE (Common Terminology Criteria for Adverse Events) grade ≥ 3, or any grade of a predefined list of events stemming from risk management of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres.
|
30 months
|
|
Progression Free Survival (PFS)
Tidsramme: 30 months
|
Time from SIRT procedure until overall progression or death
|
30 months
|
|
Hepatic Progression Free Survival (HPFS)
Tidsramme: 30 months
|
Time from SIRT procedure until progression in the liver or death
|
30 months
|
|
Overall survival (OS)
Tidsramme: 30 months
|
Time from SIRT procedure until death from any cause
|
30 months
|
|
Tumor response in the liver
Tidsramme: 3 months
|
Response as per routine practice following the guidelines for corresponding tumor type
|
3 months
|
|
Lung shunt prediction
Tidsramme: 1 month
|
Lung shunt prediction will be evaluated by comparing the predicted and actual lung shunt, either in terms of percentage or absorbed dose
|
1 month
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Administered activity
Tidsramme: 1 month
|
The technical performance of SIRT in term of administered activity in Becquerel (GBq or MBq) with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
Liver volume treated
Tidsramme: 1 month
|
The technical performance of SIRT in term of liver volume treated in mL with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
SIRT treatment approach
Tidsramme: 1 month
|
The technical performance of SIRT in term of treatment approach (selective, lobar, bi-lobar, whole liver) with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
Tumor absorbed dose
Tidsramme: 1 month
|
The technical performance of SIRT in term of tumor absorbed dose in Gray (Gy) recorded from post-treatment imaging or based on injected activity and target volume with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
Normal liver absorbed dose
Tidsramme: 1 month
|
The technical performance of SIRT in term of normal liver absorbed dose in Gray (Gy) recorded from post-treatment imaging or based on injected activity and target volume with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
The use of Q-SuiteTM in clinical practice
Tidsramme: 1 month
|
The use of Q-SuiteTM in clinical practice will be recorded based on the software which is mentioned in the description of treatment or the presence of a Q-SuiteTM generated report in the patient's medical file.
|
1 month
|
|
Number of patients downstaged to liver resection or liver transplantation
Tidsramme: 30 months
|
The number of patients downstaged to liver resection or liver transplantation will be reviewed based on the number of patients that underwent liver resection or liver transplantation after the SIRT procedure
|
30 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Patologiske processer
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Adenocarcinom
- Karcinom
- Neoplasmer, kirtel og epitel
- Neoplasmer i fordøjelsessystemet
- Leversygdomme
- Neoplasmer i leveren
- Neoplastiske processer
- Carcinom, hepatocellulært
- Neoplasma Metastase
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- T141E4
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .